Who are Irinotecan+Carboplatin/concurrent radiation's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irinotecan-carboplatin-concurrent-radiation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Irinotecan+Carboplatin/concurrent radiation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irinotecan+Carboplatin/concurrent radiation (Irinotecan+Carboplatin/concurrent radiation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination with concurrent radiation. Area: Oncology.

phase 3 Chemotherapy combination with concurrent radiation Topoisomerase I (irinotecan); DNA (carboplatin and radiation) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Irinotecan+Carboplatin/concurrent radiation (Irinotecan+Carboplatin/concurrent radiation) — West Japan Thoracic Oncology Group. Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Irinotecan+Carboplatin/concurrent radiation TARGET	Irinotecan+Carboplatin/concurrent radiation	West Japan Thoracic Oncology Group	phase 3	Chemotherapy combination with concurrent radiation	Topoisomerase I (irinotecan); DNA (carboplatin and radiation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination with concurrent radiation class)

West Japan Thoracic Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irinotecan+Carboplatin/concurrent radiation — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-carboplatin-concurrent-radiation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab